• Company
  • News
  • Investors
  • Contacts
  • Careers
polypeptide-logopolypeptide-logologo-mobilepolypeptide-logo
  • Services
    • GMP Compliance
    • Pre-GMP development
    • Production
    • Quality Assurance
    • Quality control
    • Regulatory Support
  • Commercial Manufacturing
    • Commercial products at PolyPeptide
    • Late stage development
    • Process development and optimization
    • Capacity and Capabilities
  • Custom R&D
    • Custom Research Grade Peptides
    • Radiolabeled peptide
  • Generic peptides
  • Oligos
  • Services
    • GMP Compliance
    • Pre-GMP development
    • Production
    • Quality Assurance
    • Quality control
    • Regulatory Support
  • Commercial Manufacturing
    • Commercial products at PolyPeptide
    • Late stage development
    • Process development and optimization
    • Capacity and Capabilities
  • Custom R&D
    • Custom Research Grade Peptides
    • Radiolabeled peptide
  • Generic peptides
  • Oligos
✕
  • Home
  • News
  • Media releases
  • PolyPeptide announces results of the annual General Meeting 2025

PolyPeptide announces results of the annual General Meeting 2025

9 April 2025
Media releases

Baar, 9 April 2025 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced that the shareholders approved all proposals put forward by the Board of Directors at the Company’s fourth annual General Meeting with a large majority.

The Chair of the Board of Directors of PolyPeptide Group AG (the “Company”), Peter Wilden, welcomed the shareholders at the Company’s fourth annual General Meeting (“AGM 2025”) that took place at the Chollerhalle, Zug. At the AGM 2025, a total of 26,175,680 shares with voting rights were represented, corresponding to 79.02% of the issued registered shares of the Company.

All five members of the Board of Directors proposed for re-election and the proposed new independent member of the Board of Directors, Jo LeCouilliard, were appointed for a term of office ending at the conclusion of the next annual General Meeting 2026. Peter Wilden was re-elected as Chair of the Board of Directors, and Philippe Weber and Peter Wilden were each individually re-elected as members of the Remuneration and Nomination Committee for a term of office ending at the conclusion of the next annual General Meeting 2026.

The shareholders also approved the Board of Directors’ proposal to introduce a capital band in a new art. 3a of the Company’s Articles of Association and a conditional share capital for financing purposes and finance instruments in a new art. 3c of the Company’s Articles of Association.

Further proposals of the Board of Directors that were approved at the AGM 2025 included, among others, the re-election of the Statutory Auditors and the Independent Proxy as well as the approval of the maximum aggregate amount of compensation of the Board of Directors and Executive Committee. The shareholders also granted discharge to all members of the Board of Directors and Executive Committee in office in the financial year 2024 for their activities in the financial year 2024. The shareholders approved the Management Report, Statutory Financial Statements, Consolidated Financial Statements and the report on nonfinancial matters, in each case, for the financial year 2024 as well as the Remuneration Report 2024 in a separate consultative vote.

The minutes of the AGM 2025 will be available within 15 days here. The next annual General Meeting 2026 will be held on 8 April 2026.

[…]

Download PDF (English)

Download PDF (German)

Back to news

Related posts

18 March 2025

PolyPeptide publishes invitation to the annual General Meeting 2025


Read more
13 January 2025

Cytovance Biologics and PolyPeptide Announce Collaboration for Microbial and Mammalian-Expressed Peptide Drugs


Read more
8 January 2025

Doubling of production capacity at the manufacturing site in Malmö


Read more

Polypeptide Group

INFO

COMPANY
LEADERSHIP
CONTACTS
CAREERS

NEWS

LATEST NEWS
SIGN UP FOR NEWS
EVENTS

SOCIALS

LINKEDIN
YOUTUBE
© Confidentiality 2025 PolyPeptide Group • Cookie Policy • Sitemap • Privacy policy
    • Company
    • News
    • Investors
    • Contacts
    • Careers